|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/16/21 Acorda Therapeutics Inc. 10-K 12/31/20 115:19M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.88M
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 35K
3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 46K
4: EX-10.49 Material Contract HTML 454K
5: EX-10.50 Material Contract HTML 329K
6: EX-21 Subsidiaries List HTML 32K
7: EX-23 Consent of Expert or Counsel HTML 37K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 38K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 39K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 34K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 34K
18: R1 Document and Entity Information HTML 98K
19: R2 Consolidated Balance Sheets HTML 141K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
21: R4 Consolidated Statements of Operations HTML 117K
22: R5 Consolidated Statements of Comprehensive Income HTML 54K
(Loss)
23: R6 Consolidated Statements of Changes in HTML 88K
Stockholders' Equity
24: R7 Consolidated Statements of Changes in HTML 35K
Stockholders' Equity (Parenthetical)
25: R8 Consolidated Statements of Cash Flows HTML 130K
26: R9 Organization and Business Activities HTML 35K
27: R10 Summary of Significant Accounting Policies HTML 230K
28: R11 Leases HTML 119K
29: R12 Intangible Assets and Goodwill HTML 149K
30: R13 Investments HTML 82K
31: R14 Property and Equipment HTML 78K
32: R15 Assets Held for Sale HTML 36K
33: R16 Common Stock Options and Restricted Stock HTML 212K
34: R17 Debt HTML 140K
35: R18 Liability Related to Sale of Future Royalties HTML 57K
36: R19 Corporate Restructuring HTML 51K
37: R20 Accrued Expenses and Other Current Liabilities HTML 74K
38: R21 Commitments and Contingencies HTML 90K
39: R22 Fair Value Measurements HTML 173K
40: R23 License, Research and Collaboration Agreements HTML 47K
41: R24 Income Taxes HTML 285K
42: R25 Earnings Per Share HTML 75K
43: R26 Employee Benefit Plan HTML 35K
44: R27 Summary of Significant Accounting Policies HTML 317K
(Policies)
45: R28 Summary of Significant Accounting Policies HTML 145K
(Tables)
46: R29 Leases (Tables) HTML 112K
47: R30 Intangible Assets and Goodwill (Tables) HTML 137K
48: R31 Investments (Tables) HTML 82K
49: R32 Property and Equipment (Tables) HTML 76K
50: R33 Common Stock Options and Restricted Stock (Tables) HTML 211K
51: R34 Debt (Tables) HTML 119K
52: R35 Liability Related to Sale of Future Royalties HTML 54K
(Tables)
53: R36 Corporate Restructuring (Tables) HTML 50K
54: R37 Accrued Expenses and Other Current Liabilities HTML 74K
(Tables)
55: R38 Commitments and Contingencies (Tables) HTML 83K
56: R39 Fair Value Measurements (Tables) HTML 167K
57: R40 Income Taxes (Tables) HTML 280K
58: R41 Earnings Per Share (Tables) HTML 75K
59: R42 Summary of Significant Accounting Policies - HTML 223K
Additional Information (Details)
60: R43 Summary of Significant Accounting Policies - HTML 45K
Reconciliation of Cash, Cash Equivalents and
Restricted Cash (Details)
61: R44 Summary of Significant Accounting Policies - HTML 40K
Schedule of Major Classes of Inventory (Details)
62: R45 Summary of Significant Accounting Policies - HTML 50K
Disaggregation of Revenue (Details)
63: R46 Summary of Significant Accounting Policies - HTML 40K
Summary of Allowance for Cash Discounts (Details)
64: R47 Leases - Additional Information (Details) HTML 107K
65: R48 Leases - Schedule of ROU Assets and Lease HTML 38K
Liabilities Related to Operating Leases (Details)
66: R49 Leases - Components of Lease Costs (Details) HTML 41K
67: R50 Leases - Schedule of Future Minimum Commitments HTML 51K
under all Non-Cancelable Operating Leases
(Details)
68: R51 Leases - Summary of Supplemental Cash Flow HTML 39K
Information and Non-Cash Activity Related to
Operating Leases (Details)
69: R52 Intangible Assets and Goodwill - Additional HTML 81K
Information (Details)
70: R53 Intangible Assets and Goodwill - Schedule of HTML 64K
Intangible Assets (Details)
71: R54 Intangible Assets and Goodwill - Schedule of HTML 48K
Estimated Future Amortization Expense for
Intangible Assets (Details)
72: R55 Investments - Schedule of Available-for-Sale HTML 48K
Securities (Details)
73: R56 Investments - Additional Information (Details) HTML 45K
74: R57 Investments - Schedule of Changes in Accumulated HTML 44K
Other Comprehensive (loss) Income (Details)
75: R58 Property and Equipment - Schedule of Property and HTML 70K
Equipment (Details)
76: R59 Property and Equipment - Additional Information HTML 35K
(Details)
77: R60 Assets Held for Sale - Additional Information HTML 55K
(Details)
78: R61 Common Stock Options and Restricted Stock - HTML 101K
Additional Information (Details)
79: R62 Common Stock Options and Restricted Stock - HTML 41K
Schedule of Weighted Average Assumptions Using the
Black-Scholes Option Pricing Model (Details)
80: R63 Common Stock Options and Restricted Stock - HTML 42K
Schedule of Share-based Compensation Expense
(Details)
81: R64 Common Stock Options and Restricted Stock - HTML 74K
Schedule of Stock Options Activity (Details)
82: R65 Common Stock Options and Restricted Stock - HTML 80K
Schedule of Stock Options Activity, By Exercise
Price Range (Details)
83: R66 Common Stock Options and Restricted Stock - HTML 41K
Schedule of Restricted Stock Activity (Details)
84: R67 Debt - Additional Information (Details) HTML 205K
85: R68 Debt - Summary of Outstanding Note Balances HTML 50K
(Details)
86: R69 Debt - Schedule of Interest Expense Recognized HTML 48K
Related to the Notes (Details)
87: R70 Liability Related to Sale of Future Royalties - HTML 38K
Additional Information (Details)
88: R71 Liability Related to Sale of Future Royalties - HTML 42K
Schedule of Activity Within Liability Related to
Sale of Future Royalties (Details)
89: R72 Corporate Restructuring - Additional Information HTML 42K
(Details)
90: R73 Corporate Restructuring - Summary of Restructuring HTML 40K
Costs (Details)
91: R74 Accrued Expenses and Other Current Liabilities - HTML 59K
Schedule of Accrued Expenses and Other Current
Liabilities (Details)
92: R75 Commitments and Contingencies - Summary of Minimum HTML 71K
Significant Contractual Obligations (Details)
93: R76 Commitments and Contingencies - Summary of Minimum HTML 61K
Significant Contractual Obligations
(Parenthetical) (Details)
94: R77 Commitments and Contingencies - Additional HTML 46K
Information (Details)
95: R78 Fair Value Measurements - Schedule of Assets and HTML 53K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
96: R79 Fair Value Measurements - Schedule of Contingent HTML 40K
Liabilities (Details)
97: R80 Fair Value Measurements - Additional Information HTML 52K
(Details)
98: R81 Fair Value Measurements - Schedule of Fair Value HTML 45K
Reconciliation of Derivative Liability (Details)
99: R82 License, Research and Collaboration Agreements - HTML 37K
Alkermes License - Additional Information
(Details)
100: R83 License, Research and Collaboration Agreements - HTML 49K
Supply Agreement - Additional Information
(Details)
101: R84 License, Research and Collaboration Agreements - HTML 44K
Biogen Agreement - Additional Information
(Details)
102: R85 Income Taxes - Additional Information (Details) HTML 91K
103: R86 Income Taxes - Schedule of Domestic and Foreign HTML 40K
Components of (Loss) Income Before Income Taxes
(Details)
104: R87 Income Taxes - Schedule of Benefit from Income HTML 58K
Taxes (Details)
105: R88 Income Taxes - Schedule of Reconciliation of the HTML 64K
Statutory U.S. Federal Income Tax Rate to the
Entity's Effective Income Tax Rate (Details)
106: R89 Income Taxes - Schedule of Deferred Tax Assets and HTML 80K
Liabilities (Details)
107: R90 Income Taxes - Schedule of Reconciliation of HTML 37K
Beginning and Ending Amounts of Unrecognized Tax
Benefits (Details)
108: R91 Income Taxes - Reconciliation of Beginning and HTML 38K
Ending Amounts of Valuation Allowances (Details)
109: R92 Earnings Per Share - Schedule of Computation of HTML 57K
Basic and Diluted Earnings Per Share (Details)
110: R93 Earnings Per Share - Schedule of Antidilutive HTML 37K
Securities Excluded from Calculation of Net Income
Per Diluted Share (Details)
111: R94 Employee Benefit Plan - Additional Information HTML 39K
(Details)
113: XML IDEA XML File -- Filing Summary XML 212K
17: XML XBRL Instance -- acor-10k_20201231_htm XML 3.99M
112: EXCEL IDEA Workbook of Financial Reports XLSX 163K
13: EX-101.CAL XBRL Calculations -- acor-20201231_cal XML 310K
14: EX-101.DEF XBRL Definitions -- acor-20201231_def XML 1.08M
15: EX-101.LAB XBRL Labels -- acor-20201231_lab XML 2.20M
16: EX-101.PRE XBRL Presentations -- acor-20201231_pre XML 1.65M
12: EX-101.SCH XBRL Schema -- acor-20201231 XSD 308K
114: JSON XBRL Instance as JSON Data -- MetaLinks 608± 958K
115: ZIP XBRL Zipped Folder -- 0001564590-21-013318-xbrl Zip 619K
Exhibit 21
List of Subsidiaries of the Registrant
Acorda Therapeutics Limited (UK)
Acorda Therapeutics Ireland Limited (Ireland)
Biotie Therapies AG (Switzerland)
Biotie Therapies GmbH (Germany)
Biotie Therapies, Inc. (Delaware)
Biotie Therapies Ltd. (Finland) (formerly Biotie Therapies Corp.)
Biotie Therapies International Oy (Finland)
Civitas Therapeutics, Inc. (Delaware)
MS Research & Development Corporation (Delaware)
Neuronex, Inc. (Delaware)
________________________________
Note: Acorda Therapeutics, Inc. subsidiaries may conduct business under the Acorda name as well as under their entity name or variants thereof. Acorda Therapeutics Limited, MS Research & Development Corporation and Neuronex, Inc. are dormant entities without any operations and holding no or de minimis assets.
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/01/24 Acorda Therapeutics, Inc. 10-K 12/31/23 110:17M Donnelley … Solutions/FA 3/15/23 Acorda Therapeutics, Inc. 10-K 12/31/22 113:19M Donnelley … Solutions/FA 8/16/22 Acorda Therapeutics, Inc. S-8 8/16/22 5:161K Donnelley … Solutions/FA 3/18/22 Acorda Therapeutics, Inc. 10-K 12/31/21 117:16M ActiveDisclosure/FA |